Use of fabricated microparticles to achieve a slow and constant inhibition of the chemokine receptor 2 to decrease cartilage and bone damage in a mouse ptoa model

Abstract

Purpose: Nearly half of subjects sustaining significant damage to ligaments, menisci, or articular surfaces will develop osteoarthritis (OA). After injury, clinically measurable OA can require decades to become symptomatic, therefore early diagnosis and intervention is thought to be crucial to slow or prevent subsequent OA. CCR2 has been recognized as an important potential target in OA: CCR2, its ligands CCL12 (a.k.a. MCP-5) and CCL2 (a.k.a. MCP-1, the major human circulating ligand), are significantly increased in both rodent models of OA and in humans with OA.